Bioequivalence and Food Effect Assessment of Apalutamide Tablets Relative to Erl...

연구 요약

Bioequivalence and Food Effect Assessment of Apalutamide Tablets Relative to Erleada in Healthy Chinese Male Participants.

Clinical pharmacology in drug development 학술지에 발표된 이 연구는 Li N, Wang X, Li R 외 연구팀이 수행하였습니다.

이 연구는 'Bioequivalence and Food Effect Assessment of Apalutamide Tablets Relative to Erleada in Healthy Chinese Male Participants.'에 대한 과학적 분석을 제공합니다.

핵심 내용

Apalutamide, a second-generation non-steroidal androgen receptor inhibitor, is indicated for the treatment of non-metastatic castration-resistant and metastatic hormone-sensitive prostate cancer. A study was conducted to investigate the pharmacokinetic (PK) parameters of apalutamide in healthy Chinese male participants and to evaluate the bioequivalence (BE) of the test and reference formulations (Erleada) under both fed and fasted conditions. This study was a single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover study. A total of 88 healthy Chinese male volunteers were enrolled in this study, with 32 assigned to the fasted study and 56 to the fed study. The subjects were administrated a single dose of either the test or the reference formulation in each treatment period. The PK parameters of apalutamide, including the time to peak (Tmax), peak concentration (Cmax), and the area under the concentration-time curve from time 0 to 72 h (AUC0-72 h), were calculated, and the safety of apalutamide was also assessed. The Cmax and AUC0-72 h values were comparable between the test and reference formulations under both fasted and fed conditions. The 90% confidence intervals (CIs) for Cmax and AUC0-72 h fell within the BE acceptance range of 80.00% to 125.00% under both conditions. However, Tmax in the fed condition was slightly different, with median values of 4.5 h for the test formulation and 3.5 h for the reference formulation. No serious adverse events occurred during the study, and both formulations were well tolerated under fasted and fed conditions. The test and reference formulations of apalutamide were demonstrated to be bioequivalent under both fasted and fed conditions, and were well tolerated with favorable safety profiles.

일반인을 위한 해석

구체적인 실천 사항은 담당 의사 또는 약사와 상담하시기 바랍니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 40862641)